You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

 

Online download statistics by month:

Online download statistics by month: December 2019 to January 2026

AbstractFullPdf
Dec 2019110
Jan 2020770
Feb 202026266
Mar 202055557
Apr 202010911011
May 2020959523
Jun 2020454510
Jul 2020616117
Aug 2020404010
Sep 2020606012
Oct 2020747433
Nov 2020676814
Dec 2020656527
Jan 2021909132
Feb 2021838333
Mar 2021878726
Apr 2021999929
May 2021767619
Jun 2021919139
Jul 202113813825
Aug 2021646433
Sep 2021303018
Oct 2021999943
Nov 2021495122
Dec 2021636428
Jan 2022757829
Feb 2022364322
Mar 202210511642
Apr 2022717248
May 2022505015
Jun 2022575726
Jul 2022505012
Aug 2022525716
Sep 2022484926
Oct 2022555824
Nov 2022398430
Dec 2022828215
Jan 2023606122
Feb 2023969712
Mar 202312612630
Apr 2023282919
May 2023373718
Jun 2023636312
Jul 2023454631
Aug 2023373725
Sep 2023535434
Oct 2023545439
Nov 2023424225
Dec 2023757529
Jan 2024434319
Feb 2024626221
Mar 2024505184
Apr 2024454525
May 2024555532
Jun 2024626128
Jul 2024929329
Aug 2024525624
Sep 2024394021
Oct 2024484923
Nov 2024545512
Dec 202412612917
Jan 2025717528
Feb 2025686826
Mar 202510110530
Apr 2025969822
May 2025505149
Jun 2025535319
Jul 2025110
Aug 2025110
Sep 2025110
Jan 2026220
Total428243911627